15.53
price up icon0.84%   0.13
after-market Handel nachbörslich: 15.84 0.31 +2.00%
loading
Schlusskurs vom Vortag:
$15.40
Offen:
$15.57
24-Stunden-Volumen:
1.03M
Relative Volume:
0.65
Marktkapitalisierung:
$1.38B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-3.4132
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
-0.83%
1M Leistung:
+5.15%
6M Leistung:
-24.06%
1J Leistung:
+52.40%
1-Tages-Spanne:
Value
$15.32
$15.76
1-Wochen-Bereich:
Value
$15.28
$16.17
52-Wochen-Spanne:
Value
$7.931
$25.29

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
Firmenname
Travere Therapeutics Inc
Name
Telefon
888-969-7879
Name
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Name
Mitarbeiter
385
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
TVTX's Discussions on Twitter

Vergleichen Sie TVTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TVTX
Travere Therapeutics Inc
15.53 1.37B 203.45M -351.45M -369.41M -4.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.87B 3.81B -644.79M -669.77M -6.24

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-11 Bestätigt Citigroup Buy
2025-06-11 Fortgesetzt H.C. Wainwright Buy
2025-01-10 Eingeleitet Cantor Fitzgerald Overweight
2024-10-21 Hochstufung Wells Fargo Equal Weight → Overweight
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-09-09 Hochstufung Guggenheim Neutral → Buy
2024-03-27 Herabstufung Guggenheim Buy → Neutral
2023-12-05 Hochstufung Citigroup Neutral → Buy
2023-11-20 Eingeleitet Citigroup Neutral
2023-09-22 Herabstufung Wells Fargo Overweight → Equal Weight
2023-09-21 Herabstufung William Blair Outperform → Mkt Perform
2023-09-06 Fortgesetzt Evercore ISI Outperform
2023-07-21 Eingeleitet JP Morgan Overweight
2023-06-07 Fortgesetzt Piper Sandler Neutral
2023-05-22 Eingeleitet TD Cowen Outperform
2023-05-05 Hochstufung Bryan Garnier Sell → Neutral
2023-03-01 Eingeleitet Guggenheim Buy
2023-02-21 Hochstufung Wedbush Neutral → Outperform
2022-12-14 Eingeleitet Stifel Hold
2022-12-05 Eingeleitet Wells Fargo Overweight
2022-09-21 Eingeleitet Bryan Garnier Sell
2022-07-14 Fortgesetzt Canaccord Genuity Buy
2022-03-31 Eingeleitet Piper Sandler Overweight
2022-02-28 Eingeleitet H.C. Wainwright Buy
2021-05-26 Herabstufung Wedbush Outperform → Neutral
Alle ansehen

Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten

pulisher
Jul 28, 2025

Why is Travere Therapeutics Inc. stock attracting strong analyst attentionStock Market Guidance With High Returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are Travere Therapeutics Inc. company’s key revenue driversGet timely alerts on market opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Travere Therapeutics Inc. compare to its industry peersGet alerts on the hottest market movers - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Travere Therapeutics Inc. generate profit in a changing economyOutstanding capital returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

How many analysts rate Travere Therapeutics Inc. as a “Buy”Unlock powerful stock screening for profits - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

When is Travere Therapeutics Inc. stock expected to show significant growthAccelerated capital growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Travere Therapeutics Inc. in the next 12 monthsFree Trading Strategy Suggestions - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Why Travere Therapeutics Inc. stock attracts strong analyst attentionProfitable Yet Secure Picks - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Is Travere Therapeutics Inc. a good long term investmentRapid portfolio appreciation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Travere Therapeutics Inc. stock priceExceptional profit potential - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Travere Therapeutics Inc. Stock Analysis and ForecastSuperior portfolio returns - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Travere Therapeutics Inc. stockTremendous wealth creation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Travere Therapeutics Inc. stock outlookMassive wealth growth - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX): Is Breakeven Near? - 富途牛牛

Jul 24, 2025
pulisher
Jul 22, 2025

Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN

Jul 22, 2025
pulisher
Jul 19, 2025

Nisa Investment Advisors LLC Trims Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

Where are the Opportunities in (TVTX) - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 18, 2025

Research Analysts Set Expectations for TVTX FY2025 Earnings - Defense World

Jul 18, 2025
pulisher
Jul 18, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 18, 2025
pulisher
Jul 18, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 18, 2025

Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.38
price up icon 10.28%
$37.27
price up icon 0.57%
$105.00
price up icon 3.19%
$26.74
price down icon 2.59%
$111.48
price down icon 1.16%
biotechnology ONC
$305.74
price up icon 3.81%
Kapitalisierung:     |  Volumen (24h):